{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 49,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "sparse",
  "nDataPoints": 12,
  "notes": "The slide uses a numbered list format to present key value propositions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/3",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.96,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "list",
      "text": "1. First CAR-T in AL Amyloidosis... 2. First CAR-T Overcoming Neurotoxicity... 3. 58 NXC-201 CAR-T patients... 4. IMX-110 + PD-1 combination... 5. World-class team",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c5b6dea-5009-415d-8af7-7a8e912af4bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "IMMIX Biopharma Investment Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75c45c33-6738-4eb8-b9e7-2c88611c6db0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "5c694522-db69-49e7-8254-36687d79cc5c",
      "evidence": "Numbered list of key investment highlights",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 4,
      "from": 1,
      "beatId": "c782c61d-73a9-406f-a0bd-432431ac0857",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Situation & Context",
      "beatSlug": "consultants-gambit-situation-context",
      "evidence": "Introduction to Immix Biopharma and its focus on oncology and immunology",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}